Mitoquinone mesylate targets SARS-CoV-2 infection in preclinical models
A. Petcherski, M. Sharma, S. Satta, M. Daskou, H. Vasilopoulos, C. Hugo, E. Ritou, B. J. Dillon, E. Fung, G. Garcia, C. Scafoglio, A. Purkayastha, B. Gomperts, G. A. Fishbein, V. Arumugaswami, , T. Kelesidis
Mitoquinone mesylate shows antiviral and anti-inflammatory effects against SARS-CoV-2 in preclinical models.
bioRxiv · Feb 22, 2022 · PreprintMicrobiology